{"id":158827,"date":"2019-11-21T10:15:35","date_gmt":"2019-11-21T15:15:35","guid":{"rendered":"https:\/\/patientworthy.wpengine.com\/2019\/11\/21\/two-companies-announced-partnership-develop-gene-therapies\/"},"modified":"2019-11-21T10:15:35","modified_gmt":"2019-11-21T15:15:35","slug":"two-companies-announced-partnership-develop-gene-therapies","status":"publish","type":"post","link":"https:\/\/patientworthy.com\/ru\/2019\/11\/21\/two-companies-announced-partnership-develop-gene-therapies\/","title":{"rendered":"These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies"},"content":{"rendered":"<p>According to a <a href=\"https:\/\/www.biospace.com\/article\/releases\/sarepta-and-stridebio-announce-multi-target-strategic-collaboration-to-advance-novel-gene-therapies\/\" target=\"_blank\" rel=\"noopener noreferrer\">story from BioSpace<\/a>, <strong>the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead to the development of several gene therapies for a variety of rare genetic disorders<\/strong>. As a part of this deal Sarepta will have exclusive license to StrideBio&#8217;s capsid technology. Capsids offer an improved method for developing gene therapies that use viral vectors for the delivery of genetic material. <strong>Advantages include greater potency, the ability to avoid antibodies from the immune system, and tissue tropism<\/strong>. The partners also aim to collaborate on solutions to re-dosing for patients that are being treated with adeno-associated virus (AAV)-based gene therapies.<\/p>\n<h2>Terms of Partnership<\/h2>\n<p>Under the agreement, <strong>StrideBio&#8217;s primary responsibility will be the development of capsids and product candidates, as well the manufacture of gene therapies that are ultimately selected for testing in the clinical setting<\/strong>. Some of this responsibility will also be shared with Sarepta, but this company&#8217;s primary role will be commercialization and late-stage development. Potential rare diseases that will be targeted by the partners include <strong>Niemann-Pick disease, Rett syndrome, Angelman syndrome,<\/strong> and <strong>Dravet syndrome.<\/strong> <strong>However, there is potential for up to four additional disorders to be targeted as well.<\/strong> These sorts of partnerships are intended to combined the greatest relative strengths and capabilities of the participant companies. This allows them to achieve milestones that they couldn&#8217;t reach on their own or in a much quicker time frame.<\/p>\n<h2>About Gene Therapies<\/h2>\n<p><strong>Gene therapies have gained a lot of attention in recent years as an innovative approach that has the potential to lead to major breakthroughs in the treatment of a wide variety of genetically-linked diseases and disorders<\/strong>. This has even more significant implications for the field of rare diseases, <strong>as many of the rarest syndromes are the result of genetic mutations<\/strong>. Currently, only a small number of gene therapies have achieved market approval, but they have had significant impact, and many new therapies are in development in the experimental stage.<\/p>\n<p>Hopefully this partnership will result in the creation of new and successful gene therapies for a variety of rare genetic disorders.<\/p>\n<p>&nbsp;<\/p>\n<hr \/>\n<h4 class=\"footer-text\" style=\"text-align: center;\">What are your thoughts on this partnership? <a href=\"\/?page_id=77492\">Share your stories, thoughts, and hopes with the Patient Worthy community!<\/a><\/h4>\n","protected":false},"excerpt":{"rendered":"<p>According to a story from BioSpace, the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead to the development of several gene therapies for a variety of rare genetic disorders. As a part of this deal Sarepta will have exclusive license [&hellip;]<\/p>\n","protected":false},"author":131,"featured_media":158472,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[15492,15493,15494,13224],"tags":[15495,15496,15497,15498,13213,13225],"_links":{"self":[{"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/posts\/158827"}],"collection":[{"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/comments?post=158827"}],"version-history":[{"count":0,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/posts\/158827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/media\/158472"}],"wp:attachment":[{"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/media?parent=158827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/categories?post=158827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patientworthy.com\/ru\/wp-json\/wp\/v2\/tags?post=158827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}